Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025)

Dianthus Therapeutics (DNTH) posted quarterly Net Equity Issued and Repurchased of $187000.0 for Q3 2025, up 44.96% quarter-over-quarter from $129000.0 in Q1 2025.

Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025) Analysis & Trends

Dianthus Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $187000.0 for Q3 2025.

  • In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $187000.0; the TTM figure through Sep 2025 stood at $39.5 million (changed N/A YoY), while the FY2024 annual figure was $39.2 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q3 2025 stood at $187000.0, up from $129000.0 in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $39.2 million in Q4 2024, with the low at $129000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Dianthus Therapeutics 4.97 Bn 4.57 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 187,000.00
Sep 30, 2025 187,000.00
Mar 31, 2025 129,000.00
Mar 31, 2025 129,000.00
Dec 31, 2024 39.20 Mn
Dec 31, 2024 39.20 Mn
Jun 30, 2020 64.60 Mn
Jun 30, 2020 64.60 Mn
Sep 30, 2018 40.70 Mn
Sep 30, 2018 40.70 Mn
Sep 30, 2017 2.00 Mn
Sep 30, 2017 2.00 Mn
Jun 30, 2017 19.70 Mn
Jun 30, 2017 19.70 Mn